216 related articles for article (PubMed ID: 27497990)
1. Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients.
Ferrari M; Comi C; Marino F; Magistrelli L; De Marchi F; Cantello R; Riboldazzi G; Bono G; Cosentino M
Eur J Clin Pharmacol; 2016 Nov; 72(11):1335-1341. PubMed ID: 27497990
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.
Comi C; Ferrari M; Marino F; Magistrelli L; Cantello R; Riboldazzi G; Bianchi ML; Bono G; Cosentino M
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28125015
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study.
Goetz CG; Burke PF; Leurgans S; Berry-Kravis E; Blasucci LM; Raman R; Zhou L
Arch Neurol; 2001 Feb; 58(2):209-13. PubMed ID: 11176958
[TBL] [Abstract][Full Text] [Related]
4. Influence of dopamine receptor gene polymorphisms on circulating T lymphocytes: A pilot study in healthy subjects.
Cosentino M; Ferrari M; Kustrimovic N; Rasini E; Marino F
Hum Immunol; 2015 Oct; 76(10):747-52. PubMed ID: 26429319
[TBL] [Abstract][Full Text] [Related]
5. DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients.
Zainal Abidin S; Tan EL; Chan SC; Jaafar A; Lee AX; Abd Hamid MH; Abdul Murad NA; Pakarul Razy NF; Azmin S; Ahmad Annuar A; Lim SY; Cheah PS; Ling KH; Mohamed Ibrahim N
BMC Neurol; 2015 Apr; 15():59. PubMed ID: 25896831
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease.
Wang J; Zhao C; Chen B; Liu ZL
Neurosci Lett; 2004 Jan; 355(3):193-6. PubMed ID: 14732464
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system.
Goldman JG; Goetz CG; Berry-Kravis E; Leurgans S; Zhou L
Arch Neurol; 2004 Aug; 61(8):1280-4. PubMed ID: 15313848
[TBL] [Abstract][Full Text] [Related]
8. Categorising Visual Hallucinations in Early Parkinson's Disease.
Clegg BJ; Duncan GW; Khoo TK; Barker RA; Burn DJ; Yarnall AJ; Lawson RA
J Parkinsons Dis; 2018; 8(3):447-453. PubMed ID: 30040741
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk factors for visual hallucinations in Chinese patients with Parkinson's disease.
Zhu J; Shen B; Lu L; Lan W; Pan Y; Zhang L; Dong J; Wang M; Zhang L
J Neurol Sci; 2017 Jan; 372():471-476. PubMed ID: 27823833
[TBL] [Abstract][Full Text] [Related]
10. cAMP levels in lymphocytes and CD4
Cosentino M; Kustrimovic N; Ferrari M; Rasini E; Marino F
Immunology; 2018 Mar; 153(3):337-341. PubMed ID: 28940477
[TBL] [Abstract][Full Text] [Related]
11. Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes.
Kiferle L; Ceravolo R; Petrozzi L; Rossi C; Frosini D; Rocchi A; Siciliano G; Bonuccelli U; Murri L
Neurosci Lett; 2007 Jul; 422(3):228-31. PubMed ID: 17614196
[TBL] [Abstract][Full Text] [Related]
12. Serotonin 2A receptors and visual hallucinations in Parkinson disease.
Ballanger B; Strafella AP; van Eimeren T; Zurowski M; Rusjan PM; Houle S; Fox SH
Arch Neurol; 2010 Apr; 67(4):416-21. PubMed ID: 20385906
[TBL] [Abstract][Full Text] [Related]
13. Relationship between visual hallucinations and REM sleep behavior disorder in patients with Parkinson's disease.
Meral H; Aydemir T; Ozer F; Ozturk O; Ozben S; Erol C; Cetin S; Hanoglu L; Ozkayran T; Yilsen M
Clin Neurol Neurosurg; 2007 Dec; 109(10):862-7. PubMed ID: 17913346
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for visual hallucinations in patients with Parkinson's disease.
Gama RL; de Bruin VM; de Bruin PF; Távora DG; Lopes EM; Jorge IF; Bittencourt LR; Tufik S
Neurol Res; 2015 Feb; 37(2):112-6. PubMed ID: 25002179
[TBL] [Abstract][Full Text] [Related]
15. Caudate dopaminergic denervation and visual hallucinations: evidence from a ¹²³I-FP-CIT SPECT study.
Kiferle L; Ceravolo R; Giuntini M; Linsalata G; Puccini G; Volterrani D; Bonuccelli U
Parkinsonism Relat Disord; 2014 Jul; 20(7):761-5. PubMed ID: 24787757
[TBL] [Abstract][Full Text] [Related]
16. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease.
Kurita A; Ochiai Y; Kono Y; Suzuki M; Inoue K
J Geriatr Psychiatry Neurol; 2003 Sep; 16(3):184-8. PubMed ID: 12967063
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease.
Damasceno Dos Santos EU; Duarte EBC; Miranda LMR; Asano AGC; Asano NMJ; Maia MMD; de Souza PRE
J Clin Pharmacol; 2019 Jul; 59(7):1006-1013. PubMed ID: 30794329
[TBL] [Abstract][Full Text] [Related]
18. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.
Makoff AJ; Graham JM; Arranz MJ; Forsyth J; Li T; Aitchison KJ; Shaikh S; Grünewald RA
Pharmacogenetics; 2000 Feb; 10(1):43-8. PubMed ID: 10739171
[TBL] [Abstract][Full Text] [Related]
19. Genetic substrates of psychosis in patients with Parkinson's disease: A critical review.
Lenka A; Arumugham SS; Christopher R; Pal PK
J Neurol Sci; 2016 May; 364():33-41. PubMed ID: 27084212
[TBL] [Abstract][Full Text] [Related]
20. Hallucinations and sleep disturbances in Parkinson's disease.
Kulisevsky J; Roldan E
Neurology; 2004 Oct; 63(8 Suppl 3):S28-30. PubMed ID: 15505140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
